Patents by Inventor Michael Renzi

Michael Renzi has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • NEUROPROTECTIVE PEPTIDES
    Publication number: 20090170759
    Abstract: Methods of treating diseases of the nervous system by administration of compositions having the neurological therapeutic activity of human erythropoietin are disclosed. These compositions include therapeutic agents such as peptides, peptide dimers, polypeptides, and proteins that have the full range of biological activity of human erythropoietin or only certain biological activities of erythropoietin. Improved therapeutic regimens where the erythropoietin is administered at concentrations below those required to stimulate hematopoiesis are also provided.
    Type: Application
    Filed: July 11, 2007
    Publication date: July 2, 2009
    Inventors: Virginia Smith-Swintosky, Michael Renzi, Carlos Plata-Salaman, Linda Jolliffe, Francis Farrell, Dana Johnson
  • Neuroprotective peptides
    Patent number: 7259146
    Abstract: Methods of treating diseases of the nervous system by administration of compositions having the neurological therapeutic activity of human erythropoietin are disclosed. These compositions include therapeutic agents such as peptides, peptide dimers, polypeptides, and proteins that have the full range of biological activity of human erythropoietin or only certain biological activities of erythropoietin. Improved therapeutic regimens where the erythropoietin is administered at concentrations below those required to stimulate hematopoiesis are also provided.
    Type: Grant
    Filed: May 23, 2001
    Date of Patent: August 21, 2007
    Assignee: Ortho-McNeil Pharmaceutical, Inc.
    Inventors: Virginia Smith-Swintosky, Michael Renzi, Carlos Plata-Salaman, Linda Jolliffe, Francis Farrell, Dana Johnson
  • METHODS FOR SHP1 MEDIATED NEUROPROTECTION
    Publication number: 20070065885
    Abstract: The effect of EPO on the phosphorylation of the EPO receptor, the activation of the MAP Kinase pathway, and the expression of SHP-1 were analyzed. EPO was observed to cause a decrease in the expression of its negative regulator SHP-1. The decrease observed at both the mRNA and protein level was dose dependent and persisted as long as 24 hr following EPO treatment. EPO can down regulate the expression of its own negative regulator as a means for increased potency in neurons. Assays were generated to identify compounds that are useful in regulating SHP1 activity in neural cells.
    Type: Application
    Filed: September 8, 2006
    Publication date: March 22, 2007
    Inventors: Michael Renzi, Navneeth Thirumalai, Linda Jolliffe, Francis Farrell
  • METHODS FOR SHP1 MEDIATED NEUROPROTECTION
    Publication number: 20070009967
    Abstract: The effect of EPO on the phosphorylation of the EPO receptor, the activation of the MAP Kinase pathway, and the expression of SHP-1 were analyzed. EPO was observed to cause a decrease in the expression of its negative regulator SHP-1. The decrease observed at both the mRNA and protein level was dose dependent and persisted as long as 24 hr following EPO treatment. EPO can down regulate the expression of its own negative regulator as a means for increased potency in neurons. Assays were generated to identify compounds that are useful in regulating SHP1 activity in neural cells.
    Type: Application
    Filed: September 8, 2006
    Publication date: January 11, 2007
    Inventors: Michael RENZI, Navneeth Thirumalai, Linda Jolliffe, Francis Farrell
  • Methods for SHP1 mediated neuroprotection
    Patent number: 7129267
    Abstract: The effect of EPO on the phosphorylation of the EPO receptor, the activation of the MAP Kinase pathway, and the expression of SHP-1 were analyzed. EPO was observed to cause a decrease in the expression of its negative regulator SHP-1. The decrease observed at both the mRNA and protein level was dose dependent and persisted as long as 24 hr following EPO treatment. EPO can down regulate the expression of its own negative regulator as a means for increased potency in neurons. Assays were generated to identify compounds that are useful in regulating SHP1 activity in neural cells.
    Type: Grant
    Filed: March 11, 2003
    Date of Patent: October 31, 2006
    Assignee: Janssen Pharmaceutica N.V.
    Inventors: Michael Renzi, Navneeth Thirumalai, Linda Jolliffe, Francis X. Farrell
  • Methods for SHP1 mediated neuroprotection
    Publication number: 20030232749
    Abstract: The effect of EPO on the phosphorylation of the EPO receptor, the activation of the MAP Kinase pathway, and the expression of SHP-1 were analyzed. EPO was observed to cause a decrease in the expression of its negative regulator SHP-1. The decrease observed at both the mRNA and protein level was dose dependent and persisted as long as 24 hr following EPO treatment. EPO can down regulate the expression of its own negative regulator as a means for increased potency in neurons. Assays were generated to identify compounds that are useful in regulating SHP1 activity in neural cells.
    Type: Application
    Filed: March 11, 2003
    Publication date: December 18, 2003
    Inventors: Michael Renzi, Navneeth Thirumalai, Linda Jolliffe, Francis X. Farrell
  • Neuroprotective peptides
    Publication number: 20030130197
    Abstract: Methods of treating diseases of the nervous system by administration of compositions having the neurological therapeutic activity of human erythropoietin are disclosed. These compositions include therapeutic agents such as peptides, peptide dimers, polypeptides, and proteins that have the full range of biological activity of human erythropoietin or only certain biological activities of erythropoietin. Improved therapeutic regimens where the erythropoietin is administered at concentrations below those required to stimulate hematopoiesis are also provided.
    Type: Application
    Filed: May 23, 2001
    Publication date: July 10, 2003
    Inventors: Virginia Smith-Swintosky, Michael Renzi, Carlos Plata-Salaman, Linda Jolliffe, Francis Farrell, Dana Johnson